R&D Trends

Baxalta, Symphogen ink immuno-oncology collaboration

Monday, January 4, 2016

Baxalta, a global biopharmaceutical provider dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, and Symphogen, a private biopharmaceutical company developing recombinant antibodies and antibody mixtures, have announced a broad, strategic immuno-oncology collaboration.

[Read More]

Three Questions: Piet van der Graaf, Certara

Monday, December 21, 2015

CW Weekly presents this feature as a way to put the spotlight on issues faced by executives in the clinical trial space. Staff writer Ron Rosenberg interviewed Piet van der Graaf, Pharm.D., Ph.D., vice president of quantitative systems pharmacology at Certara and former director of XenologiQ, a QSP consultancy.

[Read More]

Tetragenetics launches mAbs partnership program

Friday, December 18, 2015

Tetragenetics, an emerging biotechnology company engaged in the expression of ion channel drug targets, has announced a new partnership program for the discovery and development of therapeutic monoclonal antibodies (mAbs) directed against well-known ion channel drug targets implicated in a wide range of disease states—such as pain and autoimmune disorders.

[Read More]